A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors OphthoTech Corporation
- 27 Feb 2018 According to an OphthoTech Corporation media release, results from this study were presented at the 41st Annual Macula Society Meeting.
- 19 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.
- 19 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2019.